153 related articles for article (PubMed ID: 10919900)
21. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation.
Sandoval HP; De Castro LE; Vroman DT; Solomon KD
J Ocul Pharmacol Ther; 2006 Aug; 22(4):251-7. PubMed ID: 16910866
[TBL] [Abstract][Full Text] [Related]
22. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
Duong HV; Westfield KC; Chalkley TH
J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
[TBL] [Abstract][Full Text] [Related]
23. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery.
Solomon KD; Cheetham JK; DeGryse R; Brint SF; Rosenthal A
Ophthalmology; 2001 Feb; 108(2):331-7. PubMed ID: 11158809
[TBL] [Abstract][Full Text] [Related]
24. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial.
Heier J; Cheetham JK; Degryse R; Dirks MS; Caldwell DR; Silverstone DE; Rosenthal A
Am J Ophthalmol; 1999 Mar; 127(3):253-9. PubMed ID: 10088733
[TBL] [Abstract][Full Text] [Related]
25. Topical ketorolac 0.5% for ocular pain relief during scatter laser photocoagulation with 532 nm green laser.
Esgin H; Samut HS
J Ocul Pharmacol Ther; 2006 Dec; 22(6):460-4. PubMed ID: 17238814
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
[TBL] [Abstract][Full Text] [Related]
27. Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis.
Kosrirukvongs P; Luengchaichawange C
J Med Assoc Thai; 2004 Feb; 87(2):190-7. PubMed ID: 15061303
[TBL] [Abstract][Full Text] [Related]
28. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis.
Kiliç A; Gürler B
Can J Ophthalmol; 2006 Dec; 41(6):693-8. PubMed ID: 17224949
[TBL] [Abstract][Full Text] [Related]
29. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery.
Maca SM; Amon M; Findl O; Kahraman G; Barisani-Asenbauer T
Am J Ophthalmol; 2010 May; 149(5):777-84. PubMed ID: 20152959
[TBL] [Abstract][Full Text] [Related]
31. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
32. Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model.
Leonardi A; Busato F; Fregona I; Plebani M; Secchi AG
Br J Ophthalmol; 2000 Nov; 84(11):1228-32. PubMed ID: 11049945
[TBL] [Abstract][Full Text] [Related]
33. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.
Shulman DG; Amdahl L; Washington C; Graves A
Clin Ther; 2003 Apr; 25(4):1096-106. PubMed ID: 12809959
[TBL] [Abstract][Full Text] [Related]
34. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
Trattler W; McDonald M
Cornea; 2007 Jul; 26(6):665-9. PubMed ID: 17592313
[TBL] [Abstract][Full Text] [Related]
35. A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. Corneal Abrasion Patching Study Group.
Kaiser PK; Pineda R
Ophthalmology; 1997 Aug; 104(8):1353-9. PubMed ID: 9261326
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis.
Akpek EK; Dart JK; Watson S; Christen W; Dursun D; Yoo S; O'Brien TP; Schein OD; Gottsch JD
Ophthalmology; 2004 Mar; 111(3):476-82. PubMed ID: 15019322
[TBL] [Abstract][Full Text] [Related]
37. Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study.
Hirneiss C; Neubauer AS; Kampik A; Schönfeld CL
Graefes Arch Clin Exp Ophthalmol; 2005 Aug; 243(8):768-73. PubMed ID: 15756571
[TBL] [Abstract][Full Text] [Related]
38. Ketorolac-tobramycin combination vs fluorometholone-tobramycin combination in reducing inflammation following phacoemulsification cataract extraction with scleral tunnel incision.
Guzey M; Karadede S; Dogan Z; Satici A
Ophthalmic Surg Lasers; 2000; 31(6):451-6. PubMed ID: 11095120
[TBL] [Abstract][Full Text] [Related]
39. Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis.
Schechter BA
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):507-11. PubMed ID: 18433352
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
